Alterity Therapeutics Ltd

ATH

Company Profile

  • Business description

    Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment: research and development into Parkinsonian and other neurodegenerative disorders.

  • Contact

    500 Collins Street
    Level 15
    MelbourneVIC3000
    AUS

    T: +61 393494906

    E: [email protected]

    https://www.alteritytherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2027

    Employees

    11

Stocks News & Analysis

stocks

ASX top pick remains cheap despite weaker consumer confidence

Consumer caution dents growth, shares look cheap.
stocks

Chart of the Week: Aussie dividend yields below 10-year average

Income opportunities remain beneath the surface.
stocks

Apple earnings: A smooth transition despite continued memory and supply headwinds

Shares fell as investors digested the latest earnings.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,128.60173.701.94%
CAC 408,177.89157.581.96%
DAX 4026,437.67573.052.22%
Dow JONES (US)53,356.121,569.403.03%
FTSE 10010,829.21190.781.79%
HKSE23,919.50393.531.67%
NASDAQ25,736.51364.501.44%
Nikkei 22562,242.0653.430.09%
NZX 50 Index14,053.05269.601.96%
S&P 5007,688.62119.701.58%
S&P/ASX 2008,991.50157.001.78%
SSE Composite Index3,686.140.04-0.00%

Market Movers